{"id":7387,"date":"2025-04-10T09:06:26","date_gmt":"2025-04-10T09:06:26","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7387"},"modified":"2025-04-10T09:06:26","modified_gmt":"2025-04-10T09:06:26","slug":"research-group-on-lymphoproliferative-disorders","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/que-hacemos\/areas\/oncologia\/research-group-on-lymphoproliferative-disorders\/","title":{"rendered":"Research Group on Lymphoproliferative Disorders"},"content":{"rendered":"

\n
\n

Research Group on Lymphoproliferative Disorders<\/h3>\n<\/div>\n
<\/div><\/div>\n
Oncology Area<\/span><\/h5>\n<\/div>\n
<\/div><\/div>\n
\n
\n During the year 2019, we were able to deepen the knowledge of the role of the NOTCH1 \/ FBXW7 \/ PI3K \/ PTEN \/ AKT signaling pathway in the progression of Chronic Lymphocytic Leukemia B (CLL-B) to advanced forms. Thus, in the cell lines and in the patient’s primary cells, we observed a variation in the number of gene copies by both FISH and PCRq in the NOTCH1, FBXW7 and PTEN genes, with an inverse relationship between NOTCH1 and FBXW7 \/ PTEN<\/p>\n

– A second objective has been to analyze the clinical significance of the rearrangements of myc, bcl-2 and bcl-6 in diffuse large cell lymphoma. We have been able to verify that patients with concomitant c-myc and bcl-2 protein expression present a worse prognosis in terms of SLP and Sg than the rest<\/p>\n

– Thirdly, during 2019, the study of the mutational status of IgVH in CLL and its prognostic impact in a wide series of patients has been implemented. New molecular markers (mutations TP53, BIRC3, MYD88, NOTCH1 and SF3B1) have also been studied in CLL by new generation sequencing techniques. In addition, we have continued the collaboration in the GENOMA CLL sequencing project, with a clinical-evolutionary update<\/p>\n

– Finally, we have expanded our participation in clinical research projects in CLL, refractory lymphomas and multiple myeloma, both with the incorporation of new drugs and in the design and development of new therapeutic options
\n\n<\/div>\n<\/div>\n<\/div><\/div>